AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9163658 — intervention group
Group type: EXPERIMENTAL
Intervention: Sparfloxacin (SPX), 400 mg
Number of subjects: 31
Study 9163658 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin (CPX), 500 mg
Number of subjects: 31
Study 9163658 — intervention group
Group type: EXPERIMENTAL
Intervention: Sparfloxacin (SPX)
Number of subjects: 31
Study 9163658 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin (CPX)
Number of subjects: 31
Study 8142159 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose dexamethasone (96 mg IV bolus, followed by 96 mg orally for 3 days, then tapered over 10 days)
Number of subjects: 57
Study 8142159 — intervention group
Group type: COMPARATOR
Intervention: No dexamethasone therapy (control group)
Number of subjects: 57
Study 8142159 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose dexamethasone
Number of subjects: 57
Study 3061316 — intervention group
Group type: COMPARATOR
Intervention: Soya substitute feeding (cows' milk deliberately withheld)
Number of subjects: 487
Study 3061316 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast feeding
Number of subjects: 487
Study 3061316 — intervention group
Group type: COMPARATOR
Intervention: Environmental factors (smoking, social class, month of birth, dampness, mould, coal fires)
Number of subjects: 487
Study 3061316 — intervention group
Group type: COMPARATOR
Intervention: Eczema
Number of subjects: 487
Study 3061316 — intervention group
Group type: COMPARATOR
Intervention: IgE and IgG4 antibodies
Number of subjects: 487
Study 30292588 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodegradable Intramedullary Nailing (BIN) using polylactide-co-glycolide (PLGA) nails (Activa IM-Nail™, Bioretec Ltd., Finland)
Number of subjects: 35
Study 30292588 — intervention group
Group type: COMPARATOR
Intervention: Titanium Intramedullary Nailing (ESIN) using titanium nails (TEN®, SynthesDePuy Ltd., USA)
Number of subjects: 35
Study 30292588 — intervention group
Group type: COMPARATOR
Intervention: Titanium Intramedullary Nailing (ESIN)
Number of subjects: 35
Study 30292588 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodegradable Intramedullary Nailing (BIN)
Number of subjects: 35
Study 30292588 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 35
Study 28851403 — intervention group
Group type: EXPERIMENTAL
Intervention: mrTRG-directed management
Number of subjects: 0
Study 28851403 — intervention group
Group type: COMPARATOR
Intervention: Conventional management according to baseline MRI
Number of subjects: 0
Study 26237806 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal- and peloidotherapy as a combination treatment
Number of subjects: 0
Study 26237806 — intervention group
Group type: EXPERIMENTAL
Intervention: Upgraded combination scheme for the treatment of chronic cystitis
Number of subjects: 0
Study 23011683 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole body vibration (WBV) therapy, 20 min/day, 5 days/week for 12 months
Number of subjects: 149
Study 23011683 — intervention group
Group type: COMPARATOR
Intervention: Control group (observation alone)
Number of subjects: 149
Study 21963122 — intervention group
Group type: EXPERIMENTAL
Intervention: Scheduled Telephone Intervention (STI)
Number of subjects: 433
Study 21963122 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 433
Study 18602725 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual administration of 10 million IU of IFNalpha
Number of subjects: 0
Study 18602725 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16809727 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab added concurrently, sequentially, or not at all as adjuvant therapy
Number of subjects: 2535
Study 16809727 — intervention group
Group type: COMPARATOR
Intervention: Local laboratory testing
Number of subjects: 2535
Study 16809727 — intervention group
Group type: COMPARATOR
Intervention: Reference laboratory testing
Number of subjects: 2535
Study 15323468 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical intervention for spinal metastatic disease
Number of subjects: 0
Study 15323468 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy
Number of subjects: 0
Study 15323468 — intervention group
Group type: COMPARATOR
Intervention: Combination of surgical intervention and radiotherapy
Number of subjects: 0
Study 11064610 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil and propofol
Number of subjects: 60
Study 11064610 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl and propofol
Number of subjects: 60
Study 11064610 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil and propofol
Number of subjects: 60
Study 11064610 — intervention group
Group type: COMPARATOR
Intervention: Alfentanil, fentanyl, and sufentanil
Number of subjects: 60
Study 8646692 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment variables (not specified)
Number of subjects: 2105
Study 1484382 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management strategy
Number of subjects: 159
Study 1484382 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive reinforcement strategy
Number of subjects: 159
Study 1484382 — intervention group
Group type: COMPARATOR
Intervention: No maintenance strategy
Number of subjects: 159
Study 1484382 — intervention group
Group type: EXPERIMENTAL
Intervention: Both strategies (self-management and positive reinforcement)
Number of subjects: 159
Study 1484382 — intervention group
Group type: COMPARATOR
Intervention: Neither strategy
Number of subjects: 159
Study 6088368 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg ranitidine twice daily
Number of subjects: 197
Study 6088368 — intervention group
Group type: COMPARATOR
Intervention: 200 mg cimetidine three times a day and 400 mg at night
Number of subjects: 197
Study 30039902 — intervention group
Group type: EXPERIMENTAL
Intervention: EPG therapy
Number of subjects: 27
Study 30039902 — intervention group
Group type: EXPERIMENTAL
Intervention: EPG-informed conventional therapy
Number of subjects: 27
Study 30039902 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 27
Study 30332430 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 min/week of aerobic exercise (low-dose) for six months
Number of subjects: 23
Study 30332430 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 min/week of aerobic exercise (high-dose) for six months
Number of subjects: 23
Study 30332430 — intervention group
Group type: COMPARATOR
Intervention: Usual-care control
Number of subjects: 23
Study 27258504 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor loading dose of 360 mg
Number of subjects: 250
Study 27258504 — intervention group
Group type: COMPARATOR
Intervention: Ticagrelor loading dose of 180 mg (conventional)
Number of subjects: 250
Study 24621269 — intervention group
Group type: EXPERIMENTAL
Intervention: Medicinal bath with traditional Chinese herb formula
Number of subjects: 80
Study 24621269 — intervention group
Group type: COMPARATOR
Intervention: Perfume water bath (placebo)
Number of subjects: 80
Study 21872485 — intervention group
Group type: EXPERIMENTAL
Intervention: Triterpene ointment (OG-S10) applied at 100 mg/cm² for 14 days
Number of subjects: 24
Study 21872485 — intervention group
Group type: COMPARATOR
Intervention: Moist wound dressing (Mepilex)
Number of subjects: 24
Study 21872485 — intervention group
Group type: EXPERIMENTAL
Intervention: Triterpene ointment (OG-S10)
Number of subjects: 24
Study 19932542 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab, 24 mg/m², every 14 days for 16 weeks (total, 9 doses)
Number of subjects: 10
Study 17106276 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG + RBV
Number of subjects: 95
Study 17106276 — intervention group
Group type: COMPARATOR
Intervention: IFN + RBV
Number of subjects: 95
Study 17106276 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 95
Study 15909266 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate-clindamycin (2 mg/kg artesunate and 7 mg/kg clindamycin per dose, twice daily for 3 days)
Number of subjects: 100
Study 15909266 — intervention group
Group type: COMPARATOR
Intervention: Quinine-clindamycin (15 mg/kg quinine and 7 mg/kg clindamycin per dose, twice daily for 3 days)
Number of subjects: 100
Study 15909266 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate-clindamycin
Number of subjects: 100
Study 12483054 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% albumin prime
Number of subjects: 86
Study 12483054 — intervention group
Group type: COMPARATOR
Intervention: Crystalloid prime
Number of subjects: 86
Study 9578170 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime 320 mg/kg/day
Number of subjects: 0
Study 9578170 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime 150 mg/kg/day
Number of subjects: 0
Study 7666094 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon (2 mU/m2) subcutaneously three times per week
Number of subjects: 176
Study 7666094 — intervention group
Group type: COMPARATOR
Intervention: Control (no maintenance)
Number of subjects: 176
Study 2527543 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril
Number of subjects: 0
Study 30208372 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation targeting the left dorsal‐lateral prefrontal cortex
Number of subjects: 0
Study 28338849 — intervention group
Group type: EXPERIMENTAL
Intervention: lifestyle Matters intervention (weekly group sessions over 4 months and one to one sessions)
Number of subjects: 288
Study 28338849 — intervention group
Group type: COMPARATOR
Intervention: usual care
Number of subjects: 288
Study 25930952 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT4CBT (computerized cognitive behavioral therapy)
Number of subjects: 101
Study 25930952 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (methadone maintenance treatment alone)
Number of subjects: 101
Study 23305089 — intervention group
Group type: EXPERIMENTAL
Intervention: 0-back test
Number of subjects: 0
Study 23305089 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-back test
Number of subjects: 0
Study 22027666 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytoflavin
Number of subjects: 60
Study 19910808 — intervention group
Group type: EXPERIMENTAL
Intervention: CoreControl Rapid Thermal Exchange (RTX) at 15 degrees C
Number of subjects: 10
Study 19910808 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 degrees C standard refrigerant gel pack (P)
Number of subjects: 10
Study 19910808 — intervention group
Group type: COMPARATOR
Intervention: Control group (C) - nothing at all
Number of subjects: 10
Study 16864668 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced MR angiography
Number of subjects: 352
Study 16864668 — intervention group
Group type: COMPARATOR
Intervention: Duplex US
Number of subjects: 352
Study 12641626 — intervention group
Group type: EXPERIMENTAL
Intervention: SF-36
Number of subjects: 157
Study 12641626 — intervention group
Group type: COMPARATOR
Intervention: NHP
Number of subjects: 157
Study 10730020 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist‐directed lipid management program
Number of subjects: 51
Study 10730020 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 51
Study 8957971 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular repair
Number of subjects: 20
Study 8957971 — intervention group
Group type: COMPARATOR
Intervention: Conventional open repair
Number of subjects: 20
Study 1539751 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine 600 mg/week
Number of subjects: 3
Study 1539751 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine 300 mg/week
Number of subjects: 3
Study 1539751 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study 1539751 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine 600 mg (post-treatment)
Number of subjects: 3
Study 3516299 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide
Number of subjects: 60
Study 3516299 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 60
Study 29688139 — intervention group
Group type: EXPERIMENTAL
Intervention: Community health workers (CHWs) providing HIV and health education, counseling, social support, and facilitating communication with HIV clinics.
Number of subjects: 1799
Study 29688139 — intervention group
Group type: COMPARATOR
Intervention: Control group (no CHW intervention).
Number of subjects: 1799
Study 27753558 — intervention group
Group type: EXPERIMENTAL
Intervention: Fitbit pedometers
Number of subjects: 107
Study 27753558 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 107
Study 24778171 — intervention group
Group type: EXPERIMENTAL
Intervention: Water immersion (WI)
Number of subjects: 17
Study 24778171 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower body negative pressure (LBNP)
Number of subjects: 17
Study 24778171 — intervention group
Group type: COMPARATOR
Intervention: Water immersion (WI) and Lower body negative pressure (LBNP)
Number of subjects: 17
Study 22555575 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent vessel occlusion (PVO) for anterior circulation aneurysms presenting with mass effect (n = 11)
Number of subjects: 28
Study 22555575 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent vessel occlusion (PVO) for dissecting-type VB aneurysms presenting with subarachnoid hemorrhage (n = 6)
Number of subjects: 28
Study 22555575 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent vessel occlusion (PVO) for VB aneurysms presenting with mass effect (n = 7)
Number of subjects: 28
Study 20102926 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (3 sessions/week, 60 minutes each, at anaerobic threshold intensity)
Number of subjects: 23
Study 20102926 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 23
Study 20102926 — intervention group
Group type: COMPARATOR
Intervention: Control group (medical treatment only)
Number of subjects: 23
Study 18970937 — intervention group
Group type: EXPERIMENTAL
Intervention: Open pyloromyotomy
Number of subjects: 200
Study 18970937 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic pyloromyotomy
Number of subjects: 200
Study 18970937 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 200
Study 15967846 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan 160 mg PO BID
Number of subjects: 610
Study 15967846 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 50 mg PO TID
Number of subjects: 610
Study 15967846 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan 80 mg PO BID plus Captopril 50 mg PO TID
Number of subjects: 610
Study 15967846 — intervention group
Group type: COMPARATOR
Intervention: Baseline echocardiographic measures
Number of subjects: 610
Study 11900261 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A - 6-month supervised outpatient exercise program (3 weekly sessions of aerobic and strengthening training on non-dialysis days)
Number of subjects: 48
Study 11900261 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B - 6-month exercise program during hemodialysis
Number of subjects: 48
Study 11900261 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C - unsupervised moderate exercise program at home
Number of subjects: 48
Study 11900261 — intervention group
Group type: COMPARATOR
Intervention: Group D - patient control group (no exercise intervention)
Number of subjects: 48
Study 9918607 — intervention group
Group type: EXPERIMENTAL
Intervention: Humidified CO2 insufflation
Number of subjects: 40
Study 9918607 — intervention group
Group type: COMPARATOR
Intervention: Standard CO2 insufflation (Control)
Number of subjects: 40
Study 7675587 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle exercise materials
Number of subjects: 14
Study 7675587 — intervention group
Group type: COMPARATOR
Intervention: Structured exercise materials
Number of subjects: 14
Study 2119323 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolrestat 200 mg once daily
Number of subjects: 219
Study 2119323 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 219
Study 7428365 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg vaginal suppository of 15-methyl prostaglandin F2 alpha-methyl ester for Group 1 (9-12 weeks pregnant)
Number of subjects: 489
Study 7428365 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg vaginal suppository of 15-methyl prostaglandin F2 alpha-methyl ester for Group 2 (13-14 weeks pregnant)
Number of subjects: 489
Study 7428365 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups (1 mg and 1.5 mg)
Number of subjects: 489
Study 30453788 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-h acetylcysteine regimen (200 mg/kg over 4 h, 50 mg/kg over 8 h)
Number of subjects: 40
Study 30453788 — intervention group
Group type: COMPARATOR
Intervention: 20-h acetylcysteine regimen (200 mg/kg over 4 h, 100 mg/kg over 16 h)
Number of subjects: 40
Study 30453788 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-h acetylcysteine regimen
Number of subjects: 40
Study 30453788 — intervention group
Group type: COMPARATOR
Intervention: 20-h acetylcysteine regimen
Number of subjects: 40
Study 28493646 — intervention group
Group type: EXPERIMENTAL
Intervention: No Objective Testing Rule (NOTR)
Number of subjects: 282
Study 28493646 — intervention group
Group type: COMPARATOR
Intervention: HEART Pathway
Number of subjects: 282
Study 26887209 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous acupoint electrical stimulation (TAES) of Zusanli (ST 36)
Number of subjects: 116
Study 26887209 — intervention group
Group type: COMPARATOR
Intervention: Control group (comprehensive treatment only)
Number of subjects: 116
Study 23063327 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine (10 mg/day for the first week, and 20 mg/day for the rest of the trial)
Number of subjects: 42
Study 23063327 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 23063327 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine
Number of subjects: 42
Study 21515866 — intervention group
Group type: EXPERIMENTAL
Intervention: Conivaptan hydrochloride 20 mg once daily
Number of subjects: 49
Study 21515866 — intervention group
Group type: EXPERIMENTAL
Intervention: Conivaptan hydrochloride 20 mg twice daily
Number of subjects: 49
Study 21515866 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 18246390 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective IOPTH-guided PA (group B)
Number of subjects: 340
Study 18246390 — intervention group
Group type: COMPARATOR
Intervention: Elective PA without IOPTH guidance (group A)
Number of subjects: 340
Study 18246390 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 340
Study 16552014 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 microg/kg of recombinant activated factor VII (rFVIIa)
Number of subjects: 0
Study 16552014 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 microg/kg of recombinant activated factor VII (rFVIIa)
Number of subjects: 0
Study 16552014 — intervention group
Group type: EXPERIMENTAL
Intervention: 160 microg/kg of recombinant activated factor VII (rFVIIa)
Number of subjects: 0
Study 16552014 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15327694 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention (audit and feedback mechanism combined with optional Continuing Medical Education workshop)
Number of subjects: 0
Study 15327694 — intervention group
Group type: COMPARATOR
Intervention: Control group (no educational intervention)
Number of subjects: 0
Study 10938172 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfractionated heparin
Number of subjects: 1957
Study 10938172 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 1957
Study 10938172 — intervention group
Group type: COMPARATOR
Intervention: TIMI risk score
Number of subjects: 1957
Study 9359026 — intervention group
Group type: EXPERIMENTAL
Intervention: Samarium 153Sm lexidronam 1 mCi/kg (37 MBq/kg)
Number of subjects: 0
Study 9359026 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8471145 — intervention group
Group type: EXPERIMENTAL
Intervention: Granuflex 'E' (n = 49)
Number of subjects: 98
Study 8471145 — intervention group
Group type: COMPARATOR
Intervention: Bactigras (n = 49)
Number of subjects: 98
Study 3804905 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin plus benzylpenicillin
Number of subjects: 0
Study 3804905 — intervention group
Group type: COMPARATOR
Intervention: Standard empirical regimen of netilmicin and piperacillin
Number of subjects: 0
Study 29423372 — intervention group
Group type: EXPERIMENTAL
Intervention: Strengthened inhalation therapy for asthma
Number of subjects: 15
Study 29423372 — intervention group
Group type: COMPARATOR
Intervention: Control group (no therapy)
Number of subjects: 15
Study 26774179 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (20 mg/d for the first 15 days, 40 mg/d thereafter; n = 69)
Number of subjects: 158
Study 26774179 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 78)
Number of subjects: 158
Study 26774179 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (20 mg/d for the first 15 days, 40 mg/d thereafter)
Number of subjects: 158
Study 26774179 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 158
Study 26774179 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 158
Study 26774179 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg/d)
Number of subjects: 158
Study 25274783 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal opening wedge osteotomy
Number of subjects: 0
Study 25274783 — intervention group
Group type: COMPARATOR
Intervention: Proximal chevron osteotomy
Number of subjects: 0
Study 22654645 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training with whole body vibration (WBV) - f = 35 Hz, A = 2.5 mm
Number of subjects: 12
Study 22654645 — intervention group
Group type: COMPARATOR
Intervention: Strength training without whole body vibration (Control)
Number of subjects: 12
Study 20730368 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquatic exercise group
Number of subjects: 36
Study 20730368 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-aquatic exercise group
Number of subjects: 36
Study 20730368 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 36
Study 18319306 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (425 mg/d for 2 yr, then 850 mg/d for 2 yr)
Number of subjects: 38